Objective: The aim of this study was to explore the association of polymorphisms in DLG5 gene (G113A, C4136A and e26) with inflammatory bowel disease (IBD) risk.
Materials and methods: A total of 25 studies involved 26583 subjects were pooled for analysis. The odds ratios (ORs) and 95% confidence intervals (95% CIs) were used to pool the effect size.
Results: For G113A variant, a significant association was observed with CD risk in children (A vs. G: OR = 0.745, 95% CI = 0.569-0.977) and high quality studies (A vs. G: OR = 0.913, 95% CI = 0.850-0.981). Additionally, the results of genotype-phenotype analysis suggested G113A variant was associated with colonic involvement in CD. However, in overall population, the results indicated G113A variant was not associated with CD or UC. We also provided evidence that C4136A polymorphism had different effects on CD risk between Europeans (AA vs. CC: OR = 3.239, 95% CI = 1.149-9.136) and Asians (AA vs. CC: OR = 0.511, 95% CI = 0.299-0.873). For UC, patients with AA genotype of C4136A variant had a significantly increased UC risk (AA vs. CC: OR = 3.877, 95% CI = 1.168-12.867). Finally, no association was detected with G113A or e26 polymorphism in CD or UC patients.
Conclusions: This meta-analysis indicated G113A variant may be significantly associated with CD risk in children and colonic involvement.